Business Context and Reporting Period
This Form 8-K filing by RXi Pharmaceuticals Corporation (referred to as Phio Pharmaceuticals Corp. in metadata) covers the event date of May 31, 2018. The report addresses a regulatory notice regarding the company's continued listing status on The Nasdaq Capital Market.
Key Financial Metrics
- Stockholders' Equity: Approximately $4.7 million as of March 31, 2018 (pro forma basis).
- Nasdaq Minimum Requirement: $2.5 million in stockholders' equity per Listing Rule 5550(b)(1).
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide specific values for revenue, profit, cash flow, margins, or debt levels.
Material Changes and Compliance Status
On March 29, 2018, the company received notice of non-compliance with the minimum stockholders' equity requirement for continued listing. Following the company's submission of its financial position, Nasdaq issued a Notification Letter on May 31, 2018. The exchange has granted the company a compliance period to demonstrate adherence to the rule by no later than September 25, 2018.
Outlook, Risks, and Management Commentary
The primary risk identified is the potential delisting if the company fails to evidence compliance with the minimum stockholders' equity requirement by the September 25, 2018 deadline. Management has submitted documentation regarding the company's pro forma equity position to Nasdaq. No specific forward-looking guidance or unusual items beyond the listing status are detailed in this filing.
Investor Verification Checklist
- Verify the company's current stockholders' equity as of the most recent quarter to ensure it remains above the $2.5 million threshold.
- Monitor subsequent filings to confirm the company's compliance status with Nasdaq before the September 25, 2018 deadline.
- Review the company's full quarterly report (10-Q) for March 31, 2018, to understand the pro forma adjustments mentioned in the filing.